As part of our continued efforts to enhance the understanding of Alzheimer’s disease and invent better treatments, we have just formed a partnership with US biotech company Cerveau to develop a scanning tool to help solve one of the biggest challenges in diagnosing and treating patients suffering from Alzheimer's disease.
Tangles of the protein tau in the brain is thought to be one of the causes of Alzheimer’s disease, but today we do not have tools to show or measure the tangles in the brain. Therefore, we know little of the exact roles of the tangles in the degeneration of the brain and the development of symptoms.
With a scanning tool, researchers will be able to visualise the tangles in the patients’ brains and thereby get a much better understanding of the underlying biology of the disease and help determine effect of news drug targeting tau.
The partnership will utilise Cerveau’s imaging agent technology and our expertise in the brain and Alzheimer’s disease. The idea is to develop a so-called ligand that will tie to tau in the brain and then “light up” during brain scans thereby providing images of the of tau tangles in the brain. Such knowledge may also pave the way for treatments targeted at exactly those patients known to benefit based on the biology.